Monocyte Activation Test Market Overview and Introduction

Monocyte Activation Test market was valued at over US$ 6.5 Mn. in 2018 and is anticipated to grow at a CAGR of 12.5% from 2019 to 2030.

Monocyte activation test based on the reaction of human monocytes, now allows predicting the human response to all pyrogens (i.e. endotoxin and non-endotoxin) in vitro. The MAT can be used as alternative to animal-based pyrogen testing. The MAT is used to detect or quantify substances that activate human monocytes or monocyte cells to release endogenous mediators which have a role in the human fever response. The MAT offers significant advantages over animal-based pyrogen testing: based on the human fever response, it provides a more relevant prediction of pyrogenic activity than the rabbit pyrogen test (RPT), it can detect endotoxin and non-endotoxin pyrogens and is applicable to a greater variety of products than the RPT; moreover, it is more accurate as well as more cost and time-effective than various other pyrogen tests.

The global market is driven by the ban on animal-based pyrogen testing by several regulatory bodies and increasing in R&D activities. However, inadequate supply of MAT test kits & reagents is anticipated to somewhat restrict the lucrative growth of this market during the forecast period.

Monocyte Activation Test Market by Product & Source

On the basis of product, This market is segmented into monocyte activation test kits and reagents. Reagents accounted for the largest share of the market owing to continuously rising adoption of superior-quality reagents. Based on source, the MAT market is segmented into blood based, peripheral blood mononuclear cell (PBMC) based and cell line based. Among the sources, blood based segment accounted for the largest market share in 2017. Blood-based MAT exhibits a natural human reaction to pyrogens and provides a better estimate of pyrogenic activity.

Monocyte Activation Test Market by Application

On the basis of application, This market is segmented into medical devices, lipid parenteral, dialysis liquids, blood products and toxic/immune-modulatory drugs. End users for the global market are biotechnology industry, pharmaceuticals industry, medical devices industry and other end users. Pharmaceutical industry is expected to hold a major share of the global market due to increase in number of research studies in pharmaceutical companies to launch various new drugs. This is likely to increase use of monocyte activation tests kits and reagents and boost the growth of the segment.

Monocyte Activation Test Market by Regions

On the basis of region global market is segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of monocyte activation test, followed by Europe and Asia Pacific. North America will continue to dominate the global market in the forecast period owing to factors such as highly developed R&D scenario and strong private and public funding. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, India, and Japan. Factors such as the rising focus of major players in emerging Asian countries and rise in number of contract research organization (CRO) are driving the growth of the monocyte activation test market in this region.

Monocyte Activation Test Market Prominent Players

The prominent players in the global monocyte activation test market are Merck KGaA, Thermo Fisher Scientific, Becton, Dickinson and Company, Sanquin, Charles River Laboratories International, Inc., Microcoat Biotechnologie GmbH, SOLVIAS AG and Lonza Group among others.